In December 2021, China’s National Healthcare Security Administration (NHSA) published the 2021 National Reimbursement Drug List (2021 NRDL), implementing greater pricing discounts than those seen in 2020.
China’s National Healthcare Security Administration published the 2021 National Reimbursement Drug List, implementing greater pricing discounts than those seen in 2020. Out of 117 drugs negotiated, 74 were successfully added to the 2021 NRDL, including 67 with exclusivity.